Advertisement

Association of proton pump inhibitor use with the risk of the development or progression of albuminuria among Japanese patients with diabetes: A prospective cohort study [Diabetes Distress and Care Registry at Tenri (DDCRT 16)]

Published:February 03, 2018DOI:https://doi.org/10.1016/j.diabres.2018.01.022

      Highlights

      • It is not unclear if proton pump inhibitor (PPI) use is associated with subsequent risk of impaired renal function or the development or progression of albuminuria in patients with diabetes.
      • PPI use is not associated with the subsequent risk of estimated glomerular filtration rate decline.
      • PPI use is not also associated with the development nor progression of albuminuria in patients with diabetes.

      Abstract

      Aims

      We aimed to determine the prospective association between proton pump inhibitor (PPI) use and the subsequent risk of the development or progression of albuminuria or eGFR.

      Methods

      Longitudinal data of patients with diabetes were obtained from a large Japanese diabetes registry. To assess the independent correlation between PPI use and the development or progression of urine microalbuminuria, the time-varying Cox proportional hazards model was used with adjustment for potential confounders.

      Results

      The mean patient age, body-mass index (BMI), and hemoglobin A1c (HbA1c) levels were 65.7 y, 24.5 kg/m2, and 7.5% (57.9 mmol/mol), respectively. In 1711 patients without albuminuria, we observed 599 cases with development of albuminuria over median follow-up of 4.0 years, and in 1279 patients with microalbuminuria, 290 cases with urinary albuminuria progression over 4.0 years, and 257 eGFR decline cases over 3.8 years. PPI use was not associated with the development of albuminuria (HR = 0.88; 95%CI, 0.77–1.01; p = .058), progression of albuminuria (HR = 1.24; 95%CI, 0.87–1.79; p = .236), nor eGFR decline (HR = 1.05; 95%CI, 0.81–1.34; p = .973) even in a propensity score-adjusted model with time-varyingly updating PPI use information.

      Conclusions

      In conclusion, PPI use was not associated with the subsequent risk of development or progression of albuminuria, or eGFR decline in patients with diabetes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Diabetes Research and Clinical Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ritz E.
        • Orth S.R.
        Nephropathy in patients with type 2 diabetes mellitus.
        N Engl J Med. 1999; 341: 1127-1133
        • Gerstein H.C.
        • Mann J.F.
        • Yi Q.
        • et al.
        Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.
        JAMA. 2001; 286: 421-426
        • Forgacs I.
        • Loganayagam A.
        Overprescribing proton pump inhibitors.
        BMJ. 2008; 336: 2-3
        • Grant K.
        • Al-Adhami N.
        • Tordoff J.
        • Livesey J.
        • Barbezat G.
        • Reith D.
        Continuation of proton pump inhibitors from hospital to community.
        Pharmacy World Sci: PWS. 2006; 28: 189-193
        • Yang Y.X.
        • Lewis J.D.
        • Epstein S.
        • Metz D.C.
        Long-term proton pump inhibitor therapy and risk of hip fracture.
        JAMA. 2006; 296: 2947-2953
        • Lambert A.A.
        • Lam J.O.
        • Paik J.J.
        • Ugarte-Gil C.
        • Drummond M.B.
        • Crowell T.A.
        Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis.
        PLoS ONE. 2015; 10: e0128004
        • Dial S.
        • Alrasadi K.
        • Manoukian C.
        • Huang A.
        • Menzies D.
        Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies.
        CMAJ. 2004; 171: 33-38
        • Blank M.L.
        • Parkin L.
        • Paul C.
        • Herbison P.
        A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use.
        Kidney Int. 2014; 86: 837-844
        • Lazarus B.
        • Chen Y.
        • Wilson F.P.
        • et al.
        Proton pump inhibitor use and the risk of chronic kidney disease.
        JAMA Internal Med. 2016; 176: 238-246
        • Xie Y.
        • Bowe B.
        • Li T.
        • Xian H.
        • Balasubramanian S.
        • Al-Aly Z.
        Proton pump inhibitors and risk of incident CKD and progression to ESRD.
        J Am Soc Nephrol. 2016; 27: 3153-3163
        • Mashitani T.
        • Hayashino Y.
        • Okamura S.
        • Tsujii S.
        • Ishii H.
        Correlations between serum bilirubin levels and diabetic nephropathy progression among Japanese type 2 diabetic patients: a prospective cohort study (Diabetes Distress and Care Registry at Tenri [DDCRT 5]).
        Diabetes Care. 2014; 37: 252-258
        • Mashitani T.
        • Hayashino Y.
        • Okamura S.
        • et al.
        Diabetes treatment-related quality of life is associated with levels of self-care activities in insulin injection among Japanese patients with type 2 diabetes: Diabetes Distress and Care Registry at Tenri (DDCRT 8).
        Acta Diabetol. 2015; 52: 639-647
        • Hayashino Y.
        • Mashitani T.
        • Tsujii S.
        • Ishii H.
        • Diabetes Distress and Care Registry at Tenri Study Group
        Elevated levels of hs-CRP are associated with high prevalence of depression in Japanese patients with type 2 diabetes: the diabetes distress and care registry at Tenri (DDCRT 6).
        Diabetes Care. 2014; 37: 2459-2465
        • Committee of the Japan Diabetes Society on the Diagnostic Criteria of Diabetes M
        • Seino Y.
        • Nanjo K.
        • et al.
        Report of the committee on the classification and diagnostic criteria of diabetes mellitus.
        J Diabetes Invest. 2010; 1: 212-228
        • Matsuo S.
        • Imai E.
        • Horio M.
        • et al.
        Revised equations for estimated GFR from serum creatinine in Japan.
        Am J Kidney Dis: Off J Natl Kidney Found. 2009; 53: 982-992
        • Molitch M.E.
        • DeFronzo R.A.
        • Franz M.J.
        • et al.
        Nephropathy in diabetes.
        Diabetes Care. 2004; 27: S79-83
        • Afghahi H.
        • Cederholm J.
        • Eliasson B.
        • et al.
        Risk factors for the development of albuminuria and renal impairment in type 2 diabetes–the Swedish National Diabetes Register (NDR).
        Nephrol Dial Transplant. 2011; 26: 1236-1243
        • Antoniou T.
        • Macdonald E.M.
        • Hollands S.
        • et al.
        Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study.
        CMAJ Open. 2015; 3: E166-171
        • Ruffenach S.J.
        • Siskind M.S.
        • Lien Y.H.
        Acute interstitial nephritis due to omeprazole.
        Am J Med. 1992; 93: 472-473
        • Berney-Meyer L.
        • Hung N.
        • Slatter T.
        • Schollum J.B.
        • Kitching A.R.
        • Walker R.J.
        Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury?.
        Nephrology (Carlton). 2014; 19: 359-365
        • Praga M.
        • Gonzalez E.
        Acute interstitial nephritis.
        Kidney Int. 2010; 77: 956-961
        • Brewster U.C.
        • Perazella M.A.
        Proton pump inhibitors and the kidney: critical review.
        Clin Nephrol. 2007; 68: 65-72
        • Pham P.C.
        • Pham P.M.
        • Pham P.A.
        • et al.
        Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2.
        Clin Nephrol. 2005; 63: 429-436
        • Perazella M.A.
        • Markowitz G.S.
        Drug-induced acute interstitial nephritis.
        Nat Rev Nephrol. 2010; 6: 461-470
        • Perazella M.A.
        • Luciano R.L.
        Review of select causes of drug-induced AKI.
        Expert Rev Clin Pharmacol. 2015; 8: 367-371
        • Danziger J.
        • William J.H.
        • Scott D.J.
        • et al.
        Proton-pump inhibitor use is associated with low serum magnesium concentrations.
        Kidney Int. 2013; 83: 692-699
        • Sakaguchi Y.
        • Shoji T.
        • Hayashi T.
        • et al.
        Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease.
        Diabetes Care. 2012; 35: 1591-1597
        • Ikemura K.
        • Oshima K.
        • Enokiya T.
        • et al.
        Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study.
        Cancer Chemother Pharmacol. 2017; 79: 943-949
        • Gai Z.
        • Visentin M.
        • Hiller C.
        • et al.
        Organic cation transporter 2 overexpression may confer an increased risk of gentamicin-induced nephrotoxicity.
        Antimicrob Agents Chemother. 2016; 60: 5573-5580
        • Hacker K.
        • Maas R.
        • Kornhuber J.
        • Fromm M.F.
        • Zolk O.
        Substrate-dependent inhibition of the human organic cation transporter OCT2: a comparison of metformin with experimental substrates.
        PLoS ONE. 2015; 10: e0136451
        • Nies A.T.
        • Hofmann U.
        • Resch C.
        • Schaeffeler E.
        • Rius M.
        • Schwab M.
        Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).
        PLoS ONE. 2011; 6: e22163